AJR ARRS Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vogl, T. J.
Right arrow Articles by Lissner, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vogl, T. J.
Right arrow Articles by Lissner, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

American Journal of Roentgenology, Vol 158, 887-892, Copyright © 1992 by American Roentgen Ray Society

ARTICLES

Gadobenate dimeglumine--a new contrast agent for MR imaging: preliminary evaluation in healthy volunteers

TJ Vogl, W Pegios, C McMahon, J Balzer, J Waitzinger, G Pirovano and J Lissner
Department of Radiology, University of Munich, Germany.

Gadobenate dimeglumine (formerly known as Gd-BOPTA) is a recently developed paramagnetic contrast agent that undergoes biliary as well as renal excretion. It may, therefore, be useful in MR imaging of the liver. Its safety, tolerance, and usefulness in visualizing hepatobiliary structures were studied in eight healthy subjects. Axial abdominal images were obtained with T1-weighted spin-echo and gradient- echo sequences at 1.5 T before and after IV administration of gadobenate dimeglumine in doses of 0.005, 0.05, 0.1, and 0.2 mmol/kg body weight. Two subjects received each dose. Administration of 0.1 mmol/kg resulted in a maximum liver enhancement of 149% on the gradient- echo sequence and of 90% on the T1-weighted spin-echo sequence 60 min after injection. The contrast enhancement of the liver remained virtually constant for 2 hr. The signal-to-noise ratio of the biliary tract increased from 38 to 121 after 2 hr on gradient-echo images. In addition, there was significant contrast enhancement of the kidneys. Optimal visualization of the liver parenchyma was achieved with doses of 0.05 and 0.1 mmol gadobenate dimeglumine/kg. Mild to moderate side effects such as nausea and retching, a sense of warmth at the infusion site, and transient pruritus lasting 1 min were reported by three (38%) of the subjects. The initial results of the first application of gadobenate dimeglumine in humans are encouraging because the contrast agent appears to be reasonably well tolerated at the doses appropriate for hepatobiliary imaging. Further clinical studies of this contrast agent are warranted to assess its effect on liver lesion conspicuity and the frequency with which side effects occur.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Am. J. Roentgenol.Home page
S. H. Choi, J. M. Lee, N. C. Yu, K.-S. Suh, J.-J. Jang, S. H. Kim, and B. I. Choi
Hepatocellular Carcinoma in Liver Transplantation Candidates: Detection with Gadobenate Dimeglumine-Enhanced MRI
Am. J. Roentgenol., August 1, 2008; 191(2): 529 - 536.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
Y. K. Kim, C. S. Kim, G. H. Chung, Y.-M. Han, S. Y. Lee, S. B. Chon, and J. M. Lee
Comparison of Gadobenate Dimeglumine-Enhanced Dynamic MRI and 16-MDCT for the Detection of Hepatocellular Carcinoma
Am. J. Roentgenol., January 1, 2006; 186(1): 149 - 157.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
Y. K. Kim, H. S. Kwak, C. S. Kim, G. H. Chung, Y. M. Han, and J. M. Lee
Hepatocellular Carcinoma in Patients with Chronic Liver Disease: Comparison of SPIO-enhanced MR Imaging and 16-Detector Row CT
Radiology, December 21, 2005; (2005) 2381042193.
[Abstract] [Full Text]

Home page
 Am. J. Roentgenol.Home page
Y. K. Kim, C. S. Kim, Y. H. Lee, H. S. Kwak, and J. M. Lee
Comparison of Superparamagnetic Iron Oxide-Enhanced and Gadobenate Dimeglumine-Enhanced Dynamic MRI for Detection of Small Hepatocellular Carcinomas
Am. J. Roentgenol., May 1, 2004; 182(5): 1217 - 1223.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
G. Pirovano, A. Vanzulli, L. Marti-Bonmati, L. Grazioli, R. Manfredi, A. Greco, N. Holzknecht, H. E. Daldrup-Link, E. Rummeny, B. Hamm, et al.
Evaluation of the Accuracy of Gadobenate Dimeglumine-Enhanced MR Imaging in the Detection and Characterization of Focal Liver Lesions
Am. J. Roentgenol., October 1, 2000; 175(4): 1111 - 1120.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
J. Petersein, A. Spinazzi, A. Giovagnoni, P. Soyer, F. Terrier, R. Lencioni, C. Bartolozzi, L. Grazioli, A. Chiesa, R. Manfredi, et al.
Focal Liver Lesions: Evaluation of the Efficacy of Gadobenate Dimeglumine in MR Imaging-A Multicenter Phase III Clinical Study
Radiology, June 1, 2000; 215(3): 727 - 736.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by the American Roentgen Ray Society.